- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02948348
Study to Nivolumab Following Preoperative Chemoradiotherapy
A Phase 1b/2 Multicenter Study to Investigate the Safety, Efficacy and Proof of Concept (POC) of Nivolumab Monotherapy as a Sequential Therapy Following Preoperative Chemoradiotherapy Patients With Locally Advanced Resectable Rectal Cancer
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
[Phase Ib]
After preoperative CRT, to sequentially administer nivolumab in combination for patients with locally advanced resectable rectal cancer. To evaluate the safety of nivolumab in sequential combination therapy, the onset of dose-limiting toxicity (DLT) and the safety of subsequent surgical therapy, and to decide on a recommended dose (RD) for the phase II part.
[Phase II] PhaseⅡ is composed of 4 cohorts.
Cohort A: First-onset rectal cancer cohort (42 cases) To evaluate the efficacy and safety of nivolumab (at the RD determined in Phase Ib) in sequential combination with surgery, administered following preoperative CRT.
And to search for biomarkers related to therapeutic effects in first-onset cases. Evaluate the safety of surgical treatment.
Cohort B: Rectal cancer with localized recurrence cohort (10 cases) To conduct an exploratory evaluation of the efficacy and safety of nivolumab (at the RD determined in Phase Ib) in sequential combination with surgery, administered after preoperative CRT.
Search for biomarkers related to therapeutic effects in localized recurrence cases. Conduct an exploratory evaluation on the safety of surgical treatment.
Cohort C: Rectal cancer with resectable lung/liver metastasis cohort (10 cases) To conduct an exploratory evaluation of the efficacy and safety of nivolumab (at the RD determined in Phase Ib) in sequential combination with surgery, administered after preoperative CRT.
Search for biomarkers related to therapeutic effects in resectable lung/liver metastasis cases. Conduct an exploratory evaluation on the safety of surgical treatment.
Cohort D: First-onset rectal cancer using ipilimumab-nivolumab combination cohort (25 cases) To conduct an exploratory evaluation of the efficacy and safety of nivolumab (240 mg/body at two-week intervals) and ipilimumab (1 mg/kg at six-week intervals) after preoperative CRT, and search for biomarkers related to therapeutic effects in first-onset cases. Conduct an exploratory evaluation on the safety of surgical treatment.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Hideaki Bando, Dr
- Número de teléfono: +81-52-762-6111
- Correo electrónico: voltage_core@east.ncc.go.jp
Copia de seguridad de contactos de estudio
- Nombre: Yuichiro Tsukada, Dr
- Número de teléfono: 92331 +81-4-7133-1111
- Correo electrónico: voltage_core@east.ncc.go.jp
Ubicaciones de estudio
-
-
-
Osaka, Japón
- Reclutamiento
- Osaka National Hospital
-
-
Chiba
-
Kashiwa, Chiba, Japón
- Reclutamiento
- National Cancer Center Hospital East
-
-
Hokkaido
-
Sapporo, Hokkaido, Japón
- Reclutamiento
- Hokkaido University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria:
(A. Phase Ib and Cohorts A and D only)
A1. Rectal cancer patients who have not undergone treatment for pre-CRT tumors situated 12 cm or less from the lower edge of the AV.
A2. The primary rectal lesion is histopathologically diagnosed as adenocarcinoma.
A3. Pre-CRT clinical stage is clinical T3-4 N-any M0.
A4. Macroscopic radical resection is deemed possible on pre-CRT image diagnosis.
A5. Aged between 20 and 80 years at the time of enrollment.
(B. Cohort B only)
B1. Clinically diagnosed with local recurrence after rectal surgery.
B2. The main site of recurrence is limited to the pelvis by pre-CRT imaging diagnosis.
B3. Macroscopic radical resection is deemed possible on pre-CRT imaging diagnosis.
B4. Aged between 20 and 75 years at the time of enrollment.
(C. Cohort C only)
C1. Rectal cancer patients who have not undergone pretreatment for a pre-CRT tumor which is 12 cm or less from the lower AV.
C2. The primary rectal lesion is histopathologically diagnosed as adenocarcinoma.
C3. The pre-CRT clinical stage is clinical T3-4 N-any M1a (liver) M1a (lungs).
C4. Macroscopic curative resection of the primary rectal lesion is deemed possible on pre-CRT imaging diagnosis.
C5. A metastatic liver tumor or a metastatic lung tumor has been diagnosed as clinically resectable prior to CRT and during clinical trial enrollment.
(D. Common to all cohorts in Phase Ib and Phase II)
D1. Patients who have provided consent through a consent form.
D2. Patients whose Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) is 0 or 1 at the time of enrollment.
D3. CRT was administered:
D4. Patients whose CRT adverse events have recovered to Grade 1 or lower based on CTCAE ver.4.0. within 14 days after the end of CRT, and are expected to be able to take nivolumab (patient is still eligible even if adverse events are not restored to Grade 1, provided that the blood cell count satisfies the eligibility criteria specified in point D8).
D5. Patients with no remote metastases as confirmed by imaging at the end of CRT (testing is allowed from 14 days before the end of CRT to the trial enrollment date).
D6. For women who may become pregnant (including patients who are not menstruating due to chemically-induced menopause among other medical reasons), patients who agree to use contraception for at least 23 weeks after the last administration of the investigational drug, starting from the day they provide consent (30 days (ovulation cycle) plus five times the elimination half-life of the investigational drug).
D7. For men, patients who agree to use contraception for at least 31 weeks after the last administration of the investigational drug, starting from the day they provide consent (90 days (spermatogenesis cycle) plus five times the elimination half-life of the investigational drug).
D8. Patients who have the sufficient organ function at the time of enrollment.
Exclusion criteria
Patients diagnosed with active double cancer (synchronous double cancer and double cancer with disease-free period within five years from enrollment).
However, lesions equivalent to intraepithelial or mucosal carcinoma deemed cured by localized treatment are not classified as active double cancer.
- Patients with a history of pelvic irradiation prior to this rectal cancer treatment.
- Patients who have not given consent through the informed consent form.
- Patients deemed by the investigator to be ineligible for the trial.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Nivolumab & Ipilimumab(Only Cohort D)
chemoradiotherapy with capecitabine+ Nivolumab + Ipilimumab(Only Cohort D) + surgical therapy
|
Capecitabine:Dose of 1650mg/m2,14days, Radiation:45Gy/25 fractions, Nivolumab :240mg on day1 of each cycle, Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
Otros nombres:
For only Cohort D,1 mg/kg at six-week intervals
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Respuesta patológica completa
Periodo de tiempo: 1 año
|
La respuesta patológica completa se evaluará con la estadificación del cáncer del American Joint Committee on Cancer (AJCC)
|
1 año
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Objective response rate
Periodo de tiempo: 1 year
|
Evaluation Criteria In Solid Tumors (RECIST)
|
1 year
|
Recurrence pattern (local or distant)
Periodo de tiempo: 1 year
|
1 year
|
|
Disease-free survival (DFS)
Periodo de tiempo: 5years
|
Evaluation Criteria In Solid Tumors (RECIST)
|
5years
|
Overall survival (OS)
Periodo de tiempo: 5years
|
Evaluation Criteria In Solid Tumors (RECIST)
|
5years
|
Incidence of adverse events (AEs)
Periodo de tiempo: 1 year
|
Safety will be evaluated with CTCAE v4.0
|
1 year
|
Rate of completing the protocol therapy
Periodo de tiempo: 1 year
|
1 year
|
|
Rate of radical resection
Periodo de tiempo: 1 year
|
1 year
|
|
Safety evaluation
Periodo de tiempo: 5years
|
Safety will be evaluated with CTCAE v4.0
|
5years
|
macroscopic evaluation of (rectal cancer) resected specimen
Periodo de tiempo: 1 year
|
1 year
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Silla de estudio: Takayuki Yoshino, Dr, Gastrointestinal Oncology Division National Cancer Center Hospital East
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias
- Neoplasias por sitio
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades intestinales
- Neoplasias Intestinales
- Enfermedades Rectales
- Neoplasias colorrectales
- Neoplasias Rectales
- Mecanismos moleculares de acción farmacológica
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes antineoplásicos inmunológicos
- Inhibidores de puntos de control inmunitarios
- Capecitabina
- Nivolumab
- Ipilimumab
Otros números de identificación del estudio
- EPOC1504
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de recto
-
Queens College, The City University of New YorkReclutamientoPublicación de artículos enviados al American Journal of Public HealthEstados Unidos
-
Children's Healthcare of AtlantaTerminadoNiños que se sometieron a un trasplante de corazón antes de los 18 años | Atención recibida en Children's Healthcare of AtlantaEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
Ensayos clínicos sobre Nivolumab
-
Universitair Ziekenhuis BrusselAún no reclutando
-
Bristol-Myers SquibbReclutamientoMelanomaEspaña, Estados Unidos, Italia, Chile, Grecia, Argentina
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminadoGlioblastoma recurrenteEstados Unidos
-
HUYABIO International, LLC.Bristol-Myers SquibbReclutamientoMelanoma irresecable o metastásico | Metástasis cerebral progresivaEspaña, Estados Unidos, Italia, Japón, Bélgica, Francia, Nueva Zelanda, Brasil, Corea, república de, Australia, Alemania, Singapur, Chequia, Austria, Sudáfrica, Reino Unido, Puerto Rico
-
Jason J. Luke, MDArray BioPharmaActivo, no reclutandoMelanoma | Carcinoma de células renales | Tumor solido | Cáncer de pulmón de células no pequeñas | Carcinoma de células escamosas de cabeza y cuelloEstados Unidos
-
Brown UniversityBristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...TerminadoCáncer de cuello uterinoEstados Unidos
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkActivo, no reclutandoCarcinoma avanzado de células renalesEstados Unidos
-
Bristol-Myers SquibbTerminadoCáncer de pulmónItalia, Estados Unidos, Francia, Federación Rusa, España, Argentina, Bélgica, Brasil, Canadá, Chile, Chequia, Alemania, Grecia, Hungría, México, Países Bajos, Polonia, Rumania, Suiza, Pavo, Reino Unido
-
Dan ZandbergBristol-Myers SquibbActivo, no reclutandoCarcinoma de células escamosas de cabeza y cuelloEstados Unidos
-
Universitätsklinikum Hamburg-EppendorfCharite University, Berlin, Germany; University Hospital, Essen; Westpfalz-Clinical...Activo, no reclutando